Are we optimising outcomes in Australia’s framework for the supply of plasma-derived medicines?

Albert Farrugia
Med J Aust 2016; 205 (7): . || doi: 10.5694/mja16.00505
Published online: 3 October 2016

Australian governments endorse a policy for the evidence-based supply of plasma derivatives, which are procured from domestically collected plasma and managed through contracts between the National Blood Authority and the collection and fractionation agencies. In Australia, these are the Australian Red Cross and CSL Behring respectively. Historically, these organisations have been granted a sole supplier status by Australian governments and their activities, unlike most arrangements for service provision, have not been subject to the mainstream tender processes for government procurement.

  • Albert Farrugia1,2

  • 1 Queen Elizabeth II Medical Centre, Perth, WA
  • 2 University of Western Australia, Perth, WA


Competing interests:

I provide consultancy services to the manufacturers of biotherapies.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.